Ctrl.Alt.Thrive Podcast by Navneet
Ctrl.Alt.Thrive is the media vertical of TechThrive Ventures a global business and technology podcast and community connecting founders, entrepreneurs, venture capitalists, policymakers, and ecosystem leaders shaping the future of innovation.
With listeners across 90+ countries and a cross-platform reach of 3M+, Ctrl.Alt.Thrive is fast emerging as a leading voice in the global tech ecosystem.
Founded by Navneet Kaur, Founder & Managing Partner at TechThrive Ventures and FemTech India the platform sits at the intersection of capital, culture, and conversation. Whether you're building, leading, or investing in the future of technology, this is your space to learn, unlearn, and thrive.
Ctrl.Alt.Thrive Podcast by Navneet
Turning Period Blood Into Diagnostic Data I Qvin, CEO Mads Lillelund
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode, Navneet sits down with Mads Lillelund, CEO of Qvin, the company behind the world's first FDA-cleared diagnostic menstrual pad. Qvin turns menstrual blood one of medicine's most discarded and dismissed biological samples into clinical-grade diagnostic data.
The pad currently detects biomarkers for diabetes (A1C), cervical cancer (HPV), endometriosis, STIs, ovarian cancer, and fertility, all non-invasively, all from a single use at home. In Stanford and Roche validation studies, Qvin detected 10% more HPV cases than the gold-standard pap smear.
Mads brings over two decades of experience across enterprise tech, Fortune 500 companies, and high-growth startups into one of the most underfunded sectors in healthcare. His mission: to lead a Diagnostic Revolution by closing the gender data gap and making needle-free diagnostics accessible to the 1.8 billion people who menstruate worldwide including the 500 million experiencing period poverty.
In this conversation, we go deep into:
- How Qvin is tackling some of the most overlooked and urgent challenges in women’s health
- What it really takes to navigate FDA clearance for a category-defining, first-of-its-kind product
- Why the gender data gap remains one of the most dangerous blind spots in modern healthcare
- The future of needle-free diagnostics and what it means for 1.8 billion women worldwide
- How breakthrough innovation can scale across underserved and resource-constrained markets
- What it means to lead as a male CEO in a space historically underfunded and overlooked
- The complexity of building equitable pricing models in low-resource settings
- The realities of raising capital in FemTech and the systemic gender imbalance in venture funding
Tune in to explore what happens if Qvin succeeds at scale a future where diagnostics are fundamentally redefined, where menstruation is no longer stigmatized but standardized in medicine, and where access to care is not determined by geography or income.
This episode is brought to you in partnership with FemTech India a global women’s health ecosystem building and scaling startups to close the gender gap in emerging markets like India.
Disclaimer: The content shared in this episode is intended for general awareness and discussion purposes only. It should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal health decisions.
©️TechThrive Ventures. All rights reserved.
Newsletter - https://techthrivenewsletter.beehiiv.com/
Qvin - https://qvin.com/
Mads Lillelund - https://www.linkedin.com/in/mads-lillelund-9701278/
Connect with us
Instagram: https://www.instagram.com/ctrl.alt.thrive.podcast/
Youtube : https://www.youtube.com/@Ctrlaltthrive/videos
Connect with Navneet
Linkedin : https://www.linkedin.com/in/navneet-kaur-80109b227/
Instagram : https://www.instagram.com/nav_neeetkaur/
